semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.5-59.0,  Malaria Falciparum Malaria Vivax Malaria Above 6 months old to 59 years old Mono-infection with P. falciparum or P. vivax, with parasitemia of: P. falciparum: 1000-100 000 asexual forms per µl; P. vivax : ≥ 250 per µl Axillary temperature ≥37.5 °C or oral/rectal temperature of ≥38 °C Ability to swallow medication Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule Informed consent from the patient or from a parent or legal guardian in the case of children less than 18 years old Informed assent from any minor participant aged 12 years; and Consent for pregnancy testing from female of child-bearing potential and from their parent or guardian if under 18 years old  Severe malnutrition Mixed Plasmodium species detected by microscopy Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/WHO normalized reference values, or who has symmetrical oedema involving at least the feet or who has a Mid Upper Arm Circumference [MUAC] <110 mm) Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, HIV/AIDS) Regular medication, which may interfere with antimalarial pharmacokinetics History of hypersensitivity reactions or contraindications to any of the drug(s) being tested or used as alternative treatment Positive pregnancy test or breastfeeding; and Unable to or unwilling to take pregnancy test or to use contraception for women or child-bearing age and who are sexually active
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypophosphatasia HPP (CASES) Clinical diagnosis of HPP (with or without previous genetic test confirmation) Evidence of burden of disease (HPP) including abnormal gait, muscle weakness, pain, recurring fractures, slow healing fractures and/or bone deformities Age ≥ 18 years Able and willing to participate in the study Able to give written informed consent (CONTROLS) Healthy men and women with normal bone mineral density (defined as a DXA bone mineral density T score at the lumbar spine or total hip greater than -1) Age ≥ 18 years Able and willing to participate in the study  HPP (CASES) Individuals with BMI<18, or BMI>30 kg/m2 Other conditions known to affect serum ALP and PLP Coeliac disease, B12 deficiency, untreated hypothyroidism, Wilson's disease Taking nutritional supplements containing vitamin B6 within past two weeks History of, or current: Severe ischaemic heart disease, rheumatoid arthritis, ankylosing spondylitis, cancer (concurrent) History of, or current neurological diseases affecting the neuromuscular system including Parkinson's disease, CVA, muscular dystrophy, myasthenia, cerebral trauma, peripheral neuropathy Treatment for more than 3 months in a year or under treatment with oral corticosteroids History of any long term immobilization (duration greater than three months) Conditions or surgery which prevent the acquisition or analysis of musculoskeletal images
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Thrombus males or females, aged 18-45. 2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP<140mmHg; 50mmHg ≤DBP<90mmHg and 50 ≤ HR <110 beats / min. 3. body mass index (BMI) between 18 to 28. 4. Participant in general good health. No clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters  males or females, aged 18-45. 2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP<140mmHg; 50mmHg ≤DBP<90mmHg and 50 ≤ HR <110 beats / min. 3. body mass index (BMI) between 18 to 28. 4. Participant in general good health. No clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin > 1X ULN during screening/baseline. 2. Serum creatinine> 1X ULN during screening/baseline. 3. Abnormal coagulation function. 4. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs. 5. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening. 6. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration. 7. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive. 8.3 months prior to screening involved in any drug or medical device clinical studies or within 5 half-life of drugs before screening. 9.Female subjects who did not receive contraception at least 30 days before administration
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 13.0-60.0,  Psoriasis minimum age 13 years maximum age 60 years both males and females affected with mild, moderate and severe psoriasis  hypertension cardiovascular disorders pregnancy lactation renal failure liver failure hypersensitivity to drug
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Secondary Hyperparathyroidism Due to Renal Causes age over 20 years 2. chronic renal failure with regular dialysis 3. iPTH> 800pg/mL, Ca > 10.1 mg/dL, and P > 5.5 mg/dL 4. symptoms of bone pain, skin itching, general weakness, insomnia and osteoporosis (T score< -2.5)  pregnancy women 2. patients after kidney transplantation 3. a failure in surgery
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 65.0-75.0,  Pain Depression Suffering from musculoskeletal pain in the last 3 years Being energetic (Being independent in the daily life activities) Being able to stand up without help before 30 seconds and walk at least six meters without help Individuals with blood sugar ranging between 90-200 mg/dl prior to the application Individuals with blood pressure ranging between 130-70 mm/Hg prior to the application Not having neurological and psychiatric diseases No history of fall Being literate Not being visually-hearing impaired Being able to communicate verbally  Pependent patients Patients with psychiatric illness Patients with joint pain disease diagnosis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 3.0-4.0,  Early Childhood Caries Generally healthy children age between 3-4 of age with unremarkable medical history and at high caries risk with at least one carious lesion (precavitated or cavitated) (Agouropoulos et al 2014). The high caries risk children are chosen because it is anticipated that they will benefit more from the topical fluoride varnish application than the low caries risk children  Patients who had received professional fluoride application in the past 6 months Patients with underlying medical history or special health care needs Patient who are uncooperative or refuse the treatment Patient who are allergic to milk protein (as MI VarnishTM contains "casein, a milk protein) Patient with contraindication for fluoride varnish e.g. hypersensitivity to colophony and/or any other constituents Patient who have primary teeth with enamel hypoplasia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Crohn's Disease Vitamin D Deficiency Vitamin D Supplement Clearly diagnosed patients with CD Vitamin D deficiency (<= 20ng / ml)  Pregnancy, lactation Liver and kidney insufficiency Co-morbid with other autoimmune diseases Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes Vitamin D level is normal or high
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Ulcerative Colitis Vitamin D Deficiency Vitamin D Supplement Clearly diagnosed patients with UC Vitamin D deficiency (<= 20ng / ml)  Pregnancy, lactation Liver and kidney insufficiency Co-morbid with other autoimmune diseases Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes Vitamin D level is normal or high
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Pre-Eclampsia Fetal Growth Retardation Gestational Diabetes All pregnant women attending the nuchal translucency scan in week 11-13 of gestation as part of the national prenatal screening program  Age< 18 years Women with calcium metabolism disorders Women who gets doctor prescribed vitamin D treatment Women with chronic kidney disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Vitamin D Deficiency Critical Illness patients in intensive care units blood calcifediol concentration less than 20 ng / mL suitable for enteral feeding no ileus, vomit, or diarrhea  younger than 20 years old receive high dose vitamin D within 4 weeks (> 3000 IU pre day) hypercalemia ( > 2.6 mmol/L) body weight < 45 or > 90 kg admitted to intensive care unit before this admission within 3 months have diseases as follows: parathyroid disease, rickets, or liver cirrhosis Child C diagnosed with renal stone, tuberculosis, or sarcoidosis Non-native speaker
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-22.0,  Acute Myeloid Leukemia All patients must be enrolled on APEC14B1 and consented to Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies Patients must be less than 22 years of age at the time of study enrollment Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease Patient must have 1 of the following >= 20% bone marrow blasts (obtained within 14 days prior to enrollment) In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy < 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment) A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) ARM C: Patient must be >= 2 years of age at the time of Late Callback ARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology  Patients with myeloid neoplasms with germline predisposition are not eligible Fanconi anemia Shwachman Diamond syndrome Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Any other known bone marrow failure syndrome Any concurrent malignancy Juvenile myelomonocytic leukemia (JMML) Philadelphia chromosome positive AML Mixed phenotype acute leukemia Acute promyelocytic leukemia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-64.0,  Vitamin D Deficiency Aged (30-64) Have a medical diagnosis of VDD  Chronic diseases, such as (osteoporosis, cancer, kidney disease(due to the association between prolonged administration of VD3 and kidney stones formation), an endocrine disorder, thalassemia) Documented history of allergic reactions to Omega-3FA supplementations
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Crohn's Disease Vitamin D Deficiency Vitamin D Supplement Clearly diagnosed patients with CD Vitamin D deficiency (<= 20ng / ml)  Pregnancy, lactation Liver and kidney insufficiency Co-morbid with other autoimmune diseases Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes Vitamin D level is normal or high Receiving infliximab treatment
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-40.0,  Vitamin D Deficiency Forty five sedentry women with non specific myalgia pain The patients' ages ranged from 30 -40 years All patients have non specific muscle pain for more than 2 months They have vitamin D deficiency All patients have BMI from 25 to 34.9 kg/m2 All patients were clinically and medically stable when attending the study  Unstable cardiovascular and chest problems Patients with diseases which affect vitamin D level as a history of rheumatic or metabolic bone diseases and diabetes Patients taking drugs which affect vitamin D level as steroids and anticonvulsants drugs  Musculoskeletal disorders which may affect their physical ability to do the exercises
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pelvic Organ Prolapse Stage II-IV pelvic organ prolapse Bothersome bulge symptoms At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form English-speaking Undergoing treatment of prolapse Surgery occurring at least 7 days from date of randomization (to allow for collection of at least 7 days of preoperative accelerometer data) Able and willing to follow up at 3 months for in-office exam  Enrollment in another research study of pelvic organ prolapse Concomitant non-urogynecologic surgery Planned further surgery in the next 3 months or anticipated treatment which would result in prolonged inactivity (such as a cancer diagnosis) 3 months postoperatively
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.417-65.0,  Shared Book Reading With Specifically Named Characters v. Generically Named Characters v. no Book Control Infants will be included if they are typically developing and between 5.5 and 12.5 months of age, as well as their caregiver Parents 18-65 years old  Infants who were born more that 14 days premature. 2. Infants who with a history of neurological or visual deficits. 3. Infants with a history of seizures or a disorder that includes risk of seizures. 4. Infants with a parent that has a history of seizures of a disorder that includes risk of seizures. 5. Parents with a history of seizures or a disorder that includes risk of seizures
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  COVID 19 Associated Coagulopathy Laboratory confirmed SARS-CoV-2 infection Age ≥18 years Requires hospital admission for further clinical management Modified ISTH Overt DIC score ≥ 3  Indication for full therapeutic-dose anticoagulation Acute venous thromboembolism (deep vein thrombosis or pulmonary embolism) within prior 3 months Acute cardiovascular event within prior 3 months Acute stroke (ischemic or hemorrhagic) within prior 3 months Active major bleeding Severe thrombocytopenia (<25,000/mm3) Increased risk of bleeding, as assessed by the investigator Acute or chronic renal insufficiency with Creatinine Clearance < 30 ml/min calculated by the modified Cockcroft and Gault formula Weight < 40 kg Known allergies to ingredients contained in enoxaparin, allergy to heparin products or history of heparin induced thrombocytopenia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Cystic Fibrosis Key Completed study drug treatment in parent study (VX18-445-109); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study Key  History of study drug intolerance in parent study Other protocol defined Inclusion/